Nintedanib Newbury

Nintedanib, the active ingredient in Nintedanib Newbury, is a tyrosine kinase inhibitor presented as an unknown/unknown for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Nintedanib is indicated for several fibrotic and oncologic conditions where inhibition of multiple tyrosine kinases slows disease progression.

- Idiopathic pulmonary fibrosis: reduces decline in lung function and delays overall disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and slows worsening of fibrotic changes. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition and improves progression‑free survival.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhoea: usually mild to moderate and may improve with supportive care. - Nausea: often transient and manageable with anti‑emetics. - Decreased appetite: can lead to weight loss if persistent. - Elevated liver enzymes: requires periodic monitoring.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, indicated by marked transaminase elevation. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of myocardial infarction or stroke have been reported.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Liver function: evaluate baseline enzymes and repeat monitoring during treatment. - Renal function: assess creatinine clearance, especially in patients with pre‑existing impairment. - Gastrointestinal health: counsel patients on managing diarrhoea and dehydration. - Concomitant anticoagulants: monitor for enhanced bleeding risk. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Nintedanib can interact with other medicines, altering its exposure or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib plasma levels and increase adverse events. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): can modestly increase exposure. - Co‑administration with other anti‑angiogenic agents: additive toxicity may occur. - High‑fat meals: may affect absorption, so advise consistent intake with respect to meals.